Psychiatr. pro Praxi, 2009; 10(2): 85-88

Psychotic symptoms in methamphetamine dependent subjects

doc. MUDr. Ladislav Hosák Ph.D, Radka Maixnerová, Dagmar Valešová
Psychiatrická klinika LF UK a FN Hradec Králové

This is a review article on methamphetamine-induced psychosis. About 20 000 subjects in the Czech Republic abuse methamphetamine

(MAMP). The prevalence of psychotic states in this subpopulation is eleven times more frequent as compared to general population.

Genetic factors, premorbid personality and methamphetamine itself with its neurotoxic and neuropathophysiological effects are important

in etiopathogenesis of MAMP psychosis. The clinical picture with paranoid-hallucinatory symptoms resembles an acute episode of

schizophrenia, negative or affective signs may also be present. Most of the MAMP-induced psychotic states subsides within one week,

however up to 40 % of the patients may develop a psychosis persisting for several months. Antipsychotics are the first choice treatment

in MAMP psychosis, the second generation should be preferred to the first one. The patient´s abstinence and avoidance of stress are

necessary for a successful treatment.

Keywords: methamphetamine, psychosis, causes, symptoms, treatment.

Published: May 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hosák L, Maixnerová R, Valešová D. Psychotic symptoms in methamphetamine dependent subjects. Psychiatr. praxi. 2009;10(2):85-88.
Download citation

References

  1. Dore G, Sweeting M. Drug-induced psychosis associated with crystaline methamphetamine. Australas Psychiatry 2006; (14)1: 86-89. Go to original source... Go to PubMed...
  2. McKetin R, McLaren J, Lubman DI, et al. The prevalence o psychotic symptoms among methamphetamine users. Addiction 2006; (101)10: 1473-1478. Go to original source... Go to PubMed...
  3. Rawson RA, Gonzales RG, Brethen P. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treatment 2002; (23)2: 145-150. Go to original source... Go to PubMed...
  4. Salo R, Nordahl TE, Leamon MH, et al. Preliminary evidence of behavioral predictors of recurrent drug-induced psychosis in methamphetamine abuse. Psychiatry Research 2008; (157)1-3: 273-277. Go to original source... Go to PubMed...
  5. Úřad vlády České republiky. Výroční zpráva o stavu ve věcech drog v ČR v roce 2006 (souhrn). Praha: Úřad vlády ČR 2007; 14 s.
  6. Chen CK, Lin SK, Sham PC, et al. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Medicine 2003; (33)8: 1407-1414. Go to original source... Go to PubMed...
  7. Nešpor K. Závislost na stimulanciích. Psychiatr. pro Praxi 2008; (9)6: 273-275.
  8. McKetin R, McLaren J, Lubman DI, et al. Hostility Among Methamphetamine Users Experiencing Psychotic Symptoms. Am J Addictions 2008; (17)3: 235-240. Go to original source... Go to PubMed...
  9. Kazufumi A. Longitudinal Clinical Course Following Pharmacological Treatment of Methamphetamine Psychosis Which Persists after Long-Term Abstinence. Ann NY Acad Sci 2006; 1074: 125-134. Go to original source... Go to PubMed...
  10. Fujii D. Risk Factors for Treatment-Resistive Methamphetamine Psychosis. J Neuropsychiatry Clin Neurosci 2002; (14)2: 239-240. Go to original source...
  11. Misra L, Kofoed L. Risperidone Treatment of Methamphetamine Psychosis. Am J Psychiatry 1997; (154)8: 1170. Go to original source... Go to PubMed...
  12. Misra L, Kofoed L, Oesterheld J, et al. Olanzapine Treatment of Methamphetamine Psychosis. J Clin Psychopharmacology 2000; (20)3: 393-394. Go to original source... Go to PubMed...
  13. Yui K, Ikemoto S, Ishiguro T, et al. Studies of Amphetamine or Methamphetamine Psychosis in Japan. Ann NY Acad Sci 2000; 914: 1-12. Go to original source... Go to PubMed...
  14. Cadet JL, Krasnova IN, Jayanthi S, et al. Neurotoxicity of Substituted Amphetamines: Molecular and Cellular Mechanisms. Neurotoxicity Research 2007; (11)3,4: 183-202. Go to original source... Go to PubMed...
  15. Hashimoto T, Hashimoto K, Matsuzawa D, et al. A Functional Glutathione S-Transferase P1 Gene Polymorphism Is Associated With Methamphetamine-Induced Psychosis in Japanese Population. Am J Med Genet Part B (Neuropsychiatric Genetics) 2005; (135B)1: 5-9. Go to original source... Go to PubMed...
  16. Chen CK, Lin SK, Sham PC, et al. Morbid Risk for Psychiatric Disorder Among the Relatives of Methamphetamine Users With and Without Psychosis. Am J Med Genet Part B (Neuropsychiatric Genetics) 2005; (136B)1: 87-91. Go to original source... Go to PubMed...
  17. Kishimoto M, Ujike H, Motohashi Y, et al. The Dysbindin Gene (DTNBP1). Is Associated with Methamphetamine Psychosis. Biol Psychiatry 2008; (63)2: 191-196. Go to original source... Go to PubMed...
  18. Masaomi I, Yoshimoto S, Mori N. Neuromechanism of Developing Methamphetamine Psychosis: A Neuroimaging Study. Ann NY Acad Sci 2004; 1025: 288-295. Go to original source... Go to PubMed...
  19. Matsuzawa D, Hashimoto K, Miytake R, et al. Identification of Functional Polymorphisms in the Promoter Region of the Human PICK1 Gene and Their Association With Methamphetamine Psychosis. Am J Psychiatry 2007; (164)7: 1105-1114. Go to original source... Go to PubMed...
  20. Srisurapanont M, Ali R, Marsden J, et al. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacology 2003; (6)4: 347-352. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.